ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Buying Sirtris For $720 Million

April 28, 2008 | APPEARED IN VOLUME 86, ISSUE 17

GlaxoSmithKline has agreed to acquire Sirtris Pharmaceuticals, a Cambridge, Mass.-based biotechnology firm, for $720 million. Sirtris' drug discovery platform exploits the modulation of sirtuins, a newly discovered class of enzymes that are believed to be involved in the aging process. The company's primary focus has been on the development of SIRT1 activators, derived from the grape extract resveratrol, for the treatment of type 2 diabetes. "This acquisition continues GSK's strategy of pursuing the best new science, externally or internally, to bring new medicines to patients and value to the GSK pipeline," says Moncef Slaoui, chairman of GSK R&D. According to Slaoui, the biotech firm will become part of GSK's drug discovery organization while continuing to operate at its Cambridge facility.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment